WITHDRAWN: A Druggable Tumor Suppressor and Leukemic Stem Cell Marker
This study identifies the absence of the tumor suppressor AT2R as a key marker for chemotherapy-resistant leukemic stem cells in acute myeloid leukemia, demonstrating that epigenetic silencing of AT2R drives disease progression through fatty acid metabolism and that its pharmacological activation with the agonist buloxibutid (C21) effectively inhibits leukemogenesis and enhances chemotherapy efficacy.